Authors: Vignon, E Garnero, P Delmas, P Avouac, B Bettica, P Boers, M Ehrich, E MacKillop, N Rovati, L Serni, U Spector, T Reginster, JY

Citation: E. Vignon et al., Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers, OSTEO CART, 9(4), 2001, pp. 289-293

Authors: Truitt, KE Sperling, RS Ettinger, WH Greenwald, M DeTora, L Zeng, Q Bolognese, J Ehrich, E

Citation: Ke. Truitt et al., A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients withosteoarthritis, AGING-CLIN, 13(2), 2001, pp. 112-121

Authors: Ehrich, E Davies, G Watson, D Bolognese, J Seidenberg, B Bellamy, N

Citation: E. Ehrich et al., Clinical improvement in osteoarthritis - Reply, J RHEUMATOL, 28(8), 2001, pp. 1932-1932

Authors: Depre, M Ehrich, E Van Hecken, A De Lepeleire, I Dallob, A Wong, P Porras, A Gertz, BJ De Schepper, PJ

Citation: M. Depre et al., Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans, EUR J CL PH, 56(2), 2000, pp. 167-174

Authors: Cannon, GW Caldwell, JR Holt, P McLean, B Seidenberg, B Bolognese, J Ehrich, E Mukhopadhyay, S Daniels, B

Citation: Gw. Cannon et al., Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip, ARTH RHEUM, 43(5), 2000, pp. 978-987

Authors: Day, R Morrison, B Luza, A Castaneda, O Strusberg, A Nahir, M Helgetveit, KB Kress, B Daniels, B Bolognese, J Krupa, D Seidenberg, B Ehrich, E

Citation: R. Day et al., A randomized trial of the efficacy and tolerability of the COX-2 inhibitorrofecoxib vs ibuprofen in patients with osteoarthritis, ARCH IN MED, 160(12), 2000, pp. 1781-1787